Please use this identifier to cite or link to this item:
Title: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Authors: Argüelles-Arias, Federico
Guerra Veloz, Maria Fernanda
Perea Amarillo, Raul
Vilches-Arenas, Angel
Castro Laria, Luisa
Maldonado Pérez, Belen
Chaaro Benallal, Dina
Benítez Roldán, Antonio
Merino, Vicente
Ramirez, Gabriel
Calleja-Hernández, Miguel Angel
Caunedo Álvarez, Angel
Romero Gómez, Manuel
metadata.dc.subject.mesh: Adult
Antibodies, Monoclonal
Biosimilar Pharmaceuticals
C-Reactive Protein
Colitis, Ulcerative
Crohn Disease
Drug Substitution
Follow-Up Studies
Gastrointestinal Agents
Middle Aged
Prospective Studies
Severity of Illness Index
Time Factors
Issue Date: 2017
Abstract: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy, yet real-world switching data are currently limited. Here, we assess the effectiveness and safety of switching to CT-P13 from infliximab reference product (RP) in patients with inflammatory bowel disease. This was a prospective single-center observational study in patients with moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). All patients were switched from infliximab RP (Remicade) to CT-P13 treatment and followed up for up to 12 months. The efficacy endpoint was the change in clinical response assessed at 3-monthly intervals, according to the Harvey-Bradshaw score and partial Mayo score for patients with CD and UC, respectively. C-reactive protein (CRP) was also measured. Adverse events were monitored and recorded throughout the study. A total of 98 patients with inflammatory bowel disease (67 CD/31 UC) were included. A total of 83.6% (56/67) of patients with CD were in remission at the time of the switch and 62.7% were in remission at 12 months. The Harvey-Bradshaw score showed a significant change at 12 months (P=0.007) but no significant change was observed in median CRP at this timepoint (P=0.364). A total of 80.6% (25/31) of patients with UC were in remission at the time of the switch and 65.3% (18/28) were in remission at 12 months. No significant changes in the median partial Mayo score (P=0.058) or CRP (P=0.329) were observed at 12 months. Serious adverse events related to medication were reported in 11 (11.2%) patients. Switching from infliximab RP to CT-P13 is efficacious and well tolerated in patients with CD or UC for up to 12 months.
metadata.dc.identifier.doi: 10.1097/MEG.0000000000000953
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5640013.pdf219,61 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons